In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Probiotic Skin Care Could Be Gutsy Move In US Regulatory Environment

This article is powered by The Rose Sheet

Executive Summary

Findings that oral probiotics may not only benefit digestive health but also potentially alleviate inflammatory skin disorders are contentious but have driven uptake of probiotic ingredients by cosmetic players. Market opportunity is growing, but probiotic skin-care claims could be liabilities in the US where FDA increasingly has been citing statements about immunotherapeutic and anti-inflammatory effects in warning letters.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel